| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
40,010,000 |
| Market
Cap: |
344.49(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.64 - $8.61 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Co.'s approved drug DANYELZA® (naxitamab-gqgk) was approved by the U.S. Food and Drug Administration for the treatment, in combination with Granulocyte-Macrophage Colony-Stimulating Factor of pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
14,727 |
335,093 |
| Total Sell Value |
$0 |
$0 |
$76,904 |
$4,272,072 |
| Total People Sold |
0 |
0 |
2 |
8 |
| Total Sell Transactions |
0 |
0 |
2 |
16 |
| End Date |
2025-09-25 |
2025-06-24 |
2024-12-24 |
2023-12-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gill David N |
|
– • – |
2025-09-16 |
4 |
D |
$0.00 |
$50,095 |
D/D |
(30,905) |
0 |
|
- |
|
| Wedell-Wedellsborg Johan |
|
– • • |
2025-09-16 |
4 |
D |
$8.60 |
$39,209,404 |
I/I |
(4,559,233) |
0 |
|
- |
|
| Wedell-Wedellsborg Johan |
|
– • • |
2025-09-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(25,080) |
0 |
|
- |
|
| Wedell-Wedellsborg Johan |
|
– • • |
2025-09-16 |
4 |
D |
$8.60 |
$50,095 |
D/D |
(5,825) |
0 |
|
- |
|
| Larocca John |
SVP, General Counsel & Secry |
• – – |
2025-09-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(21,500) |
0 |
|
- |
|
| Pfreundschuh Peter P. |
EVP, CFO and Treasurer |
• – – |
2025-09-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(77,800) |
0 |
|
- |
|
| Tyagi Ashu |
|
– • – |
2025-09-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(25,080) |
0 |
|
- |
|
| Tyagi Ashu |
|
– • – |
2025-09-16 |
4 |
D |
$8.60 |
$50,095 |
D/D |
(5,825) |
0 |
|
- |
|
| Rossi Michael J |
PRESIDENT & CEO |
• • – |
2025-09-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(129,101) |
0 |
|
- |
|
| Rossi Michael J |
PRESIDENT & CEO |
• • – |
2025-09-16 |
4 |
D |
$8.60 |
$68,645 |
D/D |
(7,982) |
0 |
|
- |
|
| Healy James |
|
– • – |
2025-09-16 |
4 |
D |
$8.60 |
$18,870,791 |
I/I |
(2,194,278) |
0 |
|
- |
|
| Healy James |
|
– • – |
2025-09-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(25,080) |
0 |
|
- |
|
| Healy James |
|
– • – |
2025-09-16 |
4 |
D |
$8.60 |
$271,786 |
D/D |
(31,603) |
0 |
|
- |
|
| Wg Biotech Aps |
|
– • • |
2025-09-16 |
4 |
D |
$8.60 |
$39,209,404 |
D/D |
(4,559,233) |
0 |
|
- |
|
| Wilms Joris |
SVP & CHIEF OPERATING OFFICER |
• – – |
2025-09-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(39,301) |
0 |
|
- |
|
| Wilms Joris |
SVP & CHIEF OPERATING OFFICER |
• – – |
2025-09-16 |
4 |
D |
$8.60 |
$110,071 |
D/D |
(12,799) |
0 |
|
- |
|
| Gad Thomas |
CHIEF BUSINESS OFFICER |
• • – |
2025-09-16 |
4 |
D |
$8.60 |
$1,098,057 |
I/I |
(127,681) |
0 |
|
- |
|
| Gad Thomas |
CHIEF BUSINESS OFFICER |
• • – |
2025-09-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(60,235) |
0 |
|
- |
|
| Gad Thomas |
CHIEF BUSINESS OFFICER |
• • – |
2025-09-16 |
4 |
D |
$8.60 |
$2,111,180 |
D/D |
(245,486) |
0 |
|
- |
|
| Hamill Laura |
|
– • – |
2025-09-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(25,080) |
0 |
|
- |
|
| Hamill Laura |
|
– • – |
2025-09-16 |
4 |
D |
$8.60 |
$50,095 |
D/D |
(5,825) |
0 |
|
- |
|
| Healy James |
|
– • – |
2025-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
25,080 |
56,683 |
|
- |
|
| Wedell-Wedellsborg Johan |
|
– • • |
2025-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
25,080 |
30,905 |
|
- |
|
| Hamill Laura |
|
– • – |
2025-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
25,080 |
30,905 |
|
- |
|
| Tyagi Ashu |
|
– • – |
2025-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
25,080 |
30,905 |
|
- |
|
305 Records found
|
|
Page 1 of 13 |
|
|
